Zhaoke Ophthalmology's (HKG:6622) new drug application for core product Cyclosporine (CsA) Ophthalmic Gel has been accepted by China's National Medical Products Administration, a Monday Hong Kong bourse filing said.
The product is being developed by the ophthalmic pharmaceutical company in China for the treatment of moderate to severe dry eye disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.